BALLERUP, Denmark–(BUSINESS WIRE)–LEO Pharma, a global leader in medical dermatology, today announced that Dr. Monica Shaw, M.D., and Nathalie Joannes will join the executive leadership team adding seasoned experience and international profile to LEO Pharma. The company is on an ambitious growth journey to become a leading provider of innovative medicines helping patients with skin diseases around the world. To align with its strategic objectives, it re-organizes its executive leadership team.
Dr. Monica Shaw, M.D., will assume the position of Executive Vice President, Region Europe+, effective July 1, 2020. Shaw joins LEO Pharma from GSK/ViiV Healthcare in Singapore, where she was VP Commercial, Head of Asia Pacific Region. She is a medical doctor with broad leadership experience across commercial and medical roles. She has a proven track record of developing high performing teams and an extensive specialty experience within the pharmaceutical industry including dermatology, immunology and rare diseases. She has held several leadership positions internationally in Europe, Asia and Latin America.
“Monica Shaw’s experience in biologics, dermatology and specialty pharma will help us to be successful in our move to launch innovative treatments and become a global leader in medical dermatology. Her combination of global experience, great leadership skills and clinical background will contribute significantly to reach our ambitions,” said Catherine Mazzacco, President and CEO of LEO Pharma.
Nathalie Joannes will join LEO Pharma as Executive Vice President, Legal and Compliance and General Counsel from September 1, 2020. (Read more…) She joins LEO Pharma from Roquette Freres based at in the Paris headquarters, where she has been Group General Counsel. During Joannes’ long-standing career in the life-sciences and pharmaceutical industries, she successfully built international teams in legal, risk management and compliance for publicly traded and privately owned global companies. She holds a Juris Doctor Degree from Université de Liège, Belgium, a Master of Law from University of Pennsylvania Law School and has been admitted to the New York Bar.
“Nathalie Joannes has a proven track record in counseling international companies and her global pharma and life-science industry experience will be of great value to support the future development of LEO Pharma towards a global leadership position and a strong entry in the innovative space. She is a highly experienced lawyer and builder of strong international teams, which will help us immensely,” said Mazzacco.
Effective July 1, 2020, Guillaume Clemént, currently Executive Vice President, Region Europe+, will assume responsibility for Region International and the thrombosis business, after having successfully led Region Europe+ in the last four years.
Dr. Monica Shaw, M.D., is a medical doctor with broad leadership experience across commercial and medical roles. She has a proven track record of developing high performing teams to deliver business performance and successful drug development. Monica Shaw has extensive specialty experience within the pharma industry working within dermatology, immuno-inflammation, HIV, neurology and oncology. She has held several leadership positions in the global pharma industry located in i.e. Europe, Asia and Latin America.
Monica Shaw earned an M.D. M.A. and is a Member of the Royal College of Physicians.
VP Commercial Head Asia Pacific region, GSK/ViiV Healthcare
2018 to current
General Manager, GlaxoSmithKline
2016 – 2018
VP Global Franchise Medical Head for Specialty, GlaxoSmithKline
2014 – 2016
UK Chief Scientific Officer, Novartis
2013 – 2014
Global Therapy Area Director for Clinical Development and Business Development, Norgine
2011 – 2013
Global Clinical Director ADHD, Shire
2009 – 2011
Nathalie Joannes holds a Juris Doctor Degree from Université de Liège, a Master of Law from University of Pennsylvania Law School and has been admitted to the New York Bar since 1987. During her long-standing career as general counsel in the chemical and pharmaceutical industries, she successfully built international teams and guided listed pharma companies through the legal aspects of mergers & acquisitions, partnerships, high-risk litigations, anti-trust investigations, corporate governance and compliance.
Group General Counsel, Roquette Frères
2016 to current
EVP and Group General Counsel, IPSEN
2011 – 2015
SVP and Chief European Counsel, Genzyme
2008 – 2011
General Counsel International, Cardinal Health
2007 – 2008
Group General Counsel, Serono International
2001 – 2007
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries. In 2019, the company generated net sales of DKK 10,805 million. For more information please visit: www.leo-pharma.com
+45 3140 6180